Clinical trials: sponsored by Boehringer Ingelheim
Healthy
A Study in Healthy People to Compare Two Different Sifrol® Tablets
The main objective of this trial is to establish the bioequivalence of Sifrol® tablets manufactured at two different sites.
- Trial name
- NCT06457204
- Testing
- Pramipexole manufactured in Ingelheim, Pramipexole manufactured in Ennigerloh
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus
The objectives of this study are to monitor the safety and effectiveness of Esgliteo in Korean patients with type 2 diabetes mellitus in a routine clinical practice setting.
- Trial name
- NCT05130463
- Testing
- Empagliflozin/Linagliptin
- Where
- 30 sites in South Korea
- Volunteers
- 1,053 people
- Sponsor
- Boehringer Ingelheim
Heart Failure
Emp-Activity: Empagliflozin Functional Capacity
This is a multinational non-interventional study based on newly collected data to assess demographics, disease, and treatment pattern of patients with chronic Heart Failure (HF) in a two-cohort design: one cohort will receive…
- Trial name
- NCT05350202
- Testing
- Empagliflozin
- Where
- 350 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 3,431 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 706321 in healthy male and female subjects following oral administration of multiple rising doses for 14 days.
- Trial name
- NCT04241458
- Testing
- BI 703621, Midazolam
- Where
- Belgium
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Glioblastoma
A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma
This study is open to adults with newly diagnosed glioblastoma, a type of brain tumor. The study has two parts. Part 1 is open to people who can get their brain tumor removed by surgery.
- Trial name
- NCT05376800
- Testing
- BI 907828 (Brigimadlin)
- Where
- 7 sites in United States, Belgium and 1 more
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together
The main objective of this trial is to investigate the relative bioavailability of vicadrostat and empagliflozin when administered in combination or individually.
- Trial name
- NCT07035457
- Testing
- Vicadrostat, Jardiance®
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib
To better understand the clinical characteristics of Idiopathic Pulmonary Fibrosis (IPF) / Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)/ Progressive Fibrosing Interstitial Lung Disease (PF-ILD) patients…
- Trial name
- NCT04614441
- Testing
- OFEV®
- Where
- 26 sites in Taiwan
- Volunteers
- 214 people
- Sponsor
- Boehringer Ingelheim
Neoplasms
A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
This is a study in adults with advanced cancer (solid tumours) in whom previous treatment was not successful. The study tests 2 medicines called BI 1387446 and BI 754091. Both medicines may help the immune system fight cancer.
- Trial name
- NCT04147234
- Testing
- BI 1387446 50 μg, BI 754091, BI 1387446 100 μg
- Where
- 8 sites in United States, Spain and 1 more
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1291583 in healthy male and female subjects following oral administration of multiple rising doses over 4 weeks.
- Trial name
- NCT03868540
- Testing
- BI 1291583
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
This Study Tests How Different Doses of BI 1291583 Are Taken up in the Body and How Well They Are Tolerated
The primary objective of this trial is to investigate the safety and tolerability of BI 1291583 in healthy male subjects following oral administration of single rising doses.
- Trial name
- NCT03414008
- Testing
- BI 1291583
- Where
- Germany
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1291583 in the Blood
The main objective of this trial is to investigate the relative bioavailability of BI 1291583 in plasma when given as oral single dose together with multiple oral doses of itraconazole (Test, T) as compared to when given alone as…
- Trial name
- NCT03890887
- Testing
- BI 1291583, Itraconazole
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How BI 1291583 is Taken up by the Body
The main objective of this trial is to investigate the absolute bioavailability of BI 1291583 (test treatment T, not radio-labelled) compared with BI 1291583 (C-14) (reference treatment R).
- Trial name
- NCT06166992
- Testing
- BI 1291583, [14C]-BI 1291583
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Trial in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1291583 in healthy male and female subjects following administration of multiple rising doses over 4 weeks and to explore…
- Trial name
- NCT04866160
- Testing
- BI 1291583
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Test Whether BI 1291583 Influences the Amount of Dabigatran in the Body
The main objective of this trial is to investigate the effect of a single dose of BI 1291583 on the pharmacokinetics of a single dose of dabigatran, an efflux transporter P-glycoprotein (P-gp) substrate.
- Trial name
- NCT06791187
- Testing
- dabigatran etexilate, BI 1291583
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy People to Test How 2 Different Doses of BI 1291583 Are Taken up in the Body When Given in 3 Different Formulations
The main objective of this trial is to investigate the relative bioavailability of two different formulations of BI 1291583 (test formulations) compared to BI 1291583 reference formulation administered at two different dose…
- Trial name
- NCT06631417
- Testing
- BI 1291583
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1291583 in healthy male Japanese subjects following oral administration of single rising doses and multiple doses.
- Trial name
- NCT05183347
- Testing
- BI 1291583
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Test How Food Influences the Amount of BI 1291583 in the Blood of Healthy Men
To assess the effect of food on the pharmacokinetics of an oral tablet formulation of BI 1291583, by investigating the relative bioavailability following single dose administration under fed and fasted conditions.
- Trial name
- NCT03837964
- Testing
- BI 1291583
- Where
- Germany
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Neoplasms
Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours
Study to determine the maximum tolerated dose of BIBW 2992 when combined with backbone chemotherapies consisting in cisplatin plus paclitaxel or cisplatin plus 5 FU.
- Trial name
- NCT00716417
- Testing
- BIBW 2992
- Where
- 3 sites in Belgium
- Volunteers
- 47 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)
This observational study will investigate the efficacy and tolerability of Vargatef (Nintedanib) plus docetaxel in daily routine second-line treatment in patients with locally advanced, metastatic or locally recurrent NSCLC.
- Trial name
- NCT02392455
- Testing
- treatment
- Where
- Germany
- Volunteers
- 817 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Dose Reduction and Discontinuation With Anti-Fibrotic Medications
The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.
- Trial name
- NCT05779007
- Testing
- Pirfenidone, Nintedanib
- Where
- United States
- Volunteers
- 2,778 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.